drugset / Trial / NCT04643470
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
Timeline
- Start
- 2020-12-22
- Primary completion
- 2024-02-26
- Completion
- 2024-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 40 mg | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |